top of page


Our High Throughput Screening (HTS) department spans 2 key sites (Chesterford Park in the UK & Leiden in the NL). The department is responsible for delivery of both molecular target-based and phenotypic screening campaigns, helping to identify and qualify ‘hits’ for our client projects. Our department is led by industry experts with several years’ experience in the design and execution of Hit identification cascades – with groups and teams covering a range of different skillsets across biochemical and cellular screening techniques.

We have a strong team culture – with regularly sharing best practise and ensuring learning across our different sites to ensure a smooth and consistent client experience from a single joined-up global department.

DMPK at Charles River

Our Discovery DMPK department in the UK is a multidisciplinary team led by Pharma experienced drug discovery scientists.  Our aim is to provide expert DMPK strategy and support to projects in an efficient and flexible manner.  We value the contributions of each and every team member from gap year students to seasoned DMPK Discipline leads and everything in between (schedulers, template builders, process improvers, in vitro ADME data generation and interpretation, bioanalytical data, PK parameter determination, modelling and simulation, human dose predictions).

We have a strong team culture where the collective team share a common goal and take ownership of the day to day and future strategy whilst making the most of individual strengths.  We think in solutions whether that is troubleshooting the instruments in the lab or working out what we need to do to understand the PK/PD relationship for a specific project. 


We make a real impact on a range of integrated drug discovery projects from different therapeutic areas (CNS, oncology, respiratory…), target classes (ion channels, enzymes…) and modalities (small molecules, protein degraders…).  If you want to experience a variety of challenges and learnings there is no better place to be.


Meet Our DMPK Leadership Team

Dawn Yates Photo.jpg

Dawn Yates

Mike Briggs
Science Director, DMPK

For over 10 years I have lead the team responsible for the efficient delivery of high quality ADME and PK data and DMPK strategic guidance to integrated and stand-alone discovery programs. 


During my career at CRL I have supported drug discovery project teams in a range of therapeutic areas including, oncology, cardiovascular and metabolic diseases whilst building a comprehensive laboratory facility providing a suite of in vitro assays and bioanalytical capabilities.  I am proud to have helped train and develop the team and watch them successfully support our client projects whether their expertise is in data generation or defining DMPK strategy.


Prior to joining CRL I learnt my trade in Pharma and was a pioneer in the generation and application of in vitro ADME data to drug discovery projects.  I then joined biotech focusing on ADME in silico model generation and DMPK support to internal research projects before various acquisitions led me to further develop my career at CRL.

I am a drug metabolism and pharmacokinetics expert with 30 years of experience gained across therapeutic areas.  During this time, I have delivered the integrated DMPK package for over 20 candidate small molecules through strategic and scientific DMPK leadership. I joined our Early Discovery organization over 11 years ago and provide DMPK guidance across our discovery portfolio. 


Prior to joining Charles River, I worked in neuroscience drug discovery at GSK and pioneered the integration of PK and PD to support candidate selection.  I have directly worked on the delivery of candidate molecules in the respiratory, pain, neurological, oncology, metabolic and gastro-intestinal disease areas, and led four discovery programs to development candidate selection.

bottom of page